President and Chief Operating Officer of Acelyrin, Inc.
Robert F. Carey has served as a member of Sangamo’s Board of Directors since June 2016. Mr. Carey currently serves as President and Chief Operating Officer of Acelyrin, Inc., a biopharmaceutical company focused on identifying, acquiring, and accelerating development and commercialization of promising drug candidates. Prior to Acelyrin, Mr. Carey served as executive vice president, chief business officer for Horizon Pharma plc from March 2014 to October 2019, and served as managing director and head of the healthcare investment banking group at JMP Securities LLC, a full-service investment bank, from March 2003 to March 2014. Previously, Mr. Carey was a managing director in the healthcare groups at Dresdner Kleinwort Wasserstein and Vector Securities International, Inc., and held roles at Shearson Lehman Hutton and Ernst & Whinney. Mr. Carey also serves on the board of directors of Beyond Air, Inc. Mr. Carey received his B.S. in accounting from the University of Notre Dame.
Kenneth Hillan has served as a member of Sangamo’s Board of Directors since September 2020. Since 2019, Dr. Hillan has served as Head of Therapeutics of 23andMe, the consumer genetics and research company, leading a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases. Previously, Dr. Hillan held leadership roles in the biotechnology industry. He served at Genentech from 1994 to 2011, where he led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio, and held a number of key leadership positions in research and development, including Senior Vice President of Clinical Development, Inflammation; Vice President of Immunology, Tissue Growth and Repair (ITGR); Vice President of Development Sciences; and Vice President of Research Operations and Pathology. He also served as Genentech’s Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China. From 2011 to 2017, he was Chief Executive Officer of Achaogen, Inc., where he was also a member of the Board of Directors. He has also served on the Board of Directors of Zymeworks since February 2017, and was a member of the Board of Directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG. Dr. Hillan has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K.
Sandy Macrae, M.B., Ch.B., Ph.D., has served as Sangamo’s President and Chief Executive Officer and as a member of the Board of Directors since June 2016. He has twenty years of experience in the pharmaceutical industry most recently serving as the Global Medical Officer of Takeda Pharmaceuticals, from 2012 to March 2016, where he established and led the Global Medical Office, which encompasses medical affairs, regulatory affairs, pharmacovigilance, outcomes research and epidemiology, quantitative sciences and knowledge and informatics. From 2001 to 2012, Dr. Macrae held roles of increasing responsibility at GlaxoSmithKline, including Senior Vice President, Emerging Markets Research and Development (R&D), from 2009 to 2012. In that position, he provided expertise and resources to create a first-of-its-kind group to expand GSK’s global reach by providing R&D strategies, clinical development and regulatory resources to enter emerging markets and Asia-Pacific. From 2007 to 2008, he was Vice President, Business Development. In that position, he was responsible for scientific assessment and business development project leadership for the neurology, psychiatry, cardiovascular and metabolic therapeutic areas. Earlier in his career, he worked for SmithKline Beecham, where he was responsible for clinical development in the therapeutic areas of neurology and gastroenterology. Dr. Macrae received his B.Sc. in pharmacology and his M.B., Ch.B. with honors from Glasgow University. He is a member of the Royal College of Physicians. Dr. Macrae also earned his Ph.D. in molecular genomics at King’s College, Cambridge.
John Markels, Ph.D. has served as a member of Sangamo’s Board of Directors since February 2020. Dr. Markels has over 30 years of leadership experience in the pharmaceutical industry. He currently serves as President of Global Vaccines at Merck, where he leads an integrated team dedicated to discovery and development, supply and access, and global marketing and long-term strategy for the vaccines portfolio. Earlier roles at Merck included President, Latin America, as well as a long career in senior leadership positions in major regions worldwide in manufacturing technology, operations and strategy, business development, alliance management, and supply chain. Dr. Markels received his Ph.D. in chemical engineering from the University of California, Berkeley and his B.S. in chemical engineering from the University of Delaware.
President and Chief Executive Officer of IntraBio
James R. Meyers has served as a member of Sangamo’s Board of Directors since November 2019 and has over 30 years of commercial leadership experience in the biotechnology industry. Mr. Myers serves as President and Chief Executive Officer at IntraBio, a biopharmaceutical company focused on novel therapies for neurodegenerative diseases. Prior to IntraBio, Mr. Meyers served as Gilead’s Executive Vice President of Worldwide Commercial Operations, where he was responsible for global commercial activities, including pricing and market access in North America, Europe, Middle East, Australia and Japan. At Gilead, he successfully led several important product launches in the HIV and hepatitis C therapeutic areas. Prior to Gilead, Mr. Meyers held positions of increasing responsibility with Zeneca Pharmaceuticals and Astra USA. He currently serves on the Board of Directors of two public companies, Arbutus Biopharma Corp. and CytomX Therapeutics, and he remains an active advisor to several major biopharmaceutical companies. Mr. Meyers holds a B.S. in Economics from Boston College.
H. Stewart Parker has served as a member of our Board of Directors since June 2014. Ms. Parker has over 30 years of experience in the biotechnology industry . She served as the chief executive officer of The Infectious Disease Research Institute (IDRI), a not-for-profit global health research institute from March 2011 to December 2013. In 1992, Ms. Parker founded Targeted Genetics Corporation, a publicly traded Seattle -based biopharmaceutical company formed to develop gene-based treatments for acquired and inherited diseases that became a world leader in AAV gene therapy. She held the position of President and CEO and was a member of its board of directors from the company's inception until November 2008. Prior to founding Targeted Genetics, Ms. Parker served in various capacities at Immunex from August 1981 through December 1991, most recently as vice president, corporate development. From February 1991 to January 1993, Ms. Parker served as president and a director of Receptech Corporation, a company formed by Immunex in 1989 to accelerate the development of soluble cytokine receptor products. She has served on the board of directors and the executive committee of BIO, the primary trade organization for the biotechnology industry. She currently serves as a member of the board of directors for several for-profit and non-profit companies including C3 Jian Inc, Oncogenex Technologies Inc and IDRI and on the advisory boards of the University of Washington Foster School of Business and College of Arts & Sciences. Ms. Parker received her B.A. and M.B.A. from the University of Washington.
Saira Ramasastry has served as a member of Sangamo’s Board of Directors since June 2012. Ms. Ramasastry has served as Managing Partner of Life Sciences Advisory, LLC, a company that she founded to provide strategic advice, business development solutions and innovative financing strategies for the life science industry since April 2009. Ms. Ramasastry also serves on the Industry Advisory Board of the Michael J. Fox Foundation for Parkinson’s Research, and as business and sustainability lead for the European Prevention of Alzheimer’s Dementia consortium. She is currently a member of the board of directors for VIR Biotechnology, Glenmark Pharmaceuticals, and Akous. Ms. Ramasastry was an investment banker with Merrill Lynch & Co., Inc. where she helped establish the biotechnology practice and was responsible for origination of mergers and acquisitions, strategic and capital markets transactions from August 1999 to March 2009. Prior to joining Merrill Lynch she served as a financial analyst in the mergers and acquisitions group at Wasserstein Perella & Co., an investment banking firm, from July 1997 to September 1998.
Ms. Ramasastry received her B.A. in economics with honors and distinction and an M.S. in management science and engineering from Stanford University, as well as an M. Phil. in management studies from the University of Cambridge where she is a guest lecturer for the Bioscience Enterprise Programme. Ms. Ramasastry is also a Health Innovator Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.
Karen Smith, MD, PhD, MBA, has served as a member of Sangamo’s Board of Directors since June 2018. Dr. Smith has over 20 years of biopharmaceutical industry experience in the United States, Europe, Canada and Asia. She has overseen more than 50 clinical trials and more than 20 regulatory approvals leading to global product launches of small molecules, biologics and devices. Most recently, she served as Executive Vice President, Global Head R&D, and Chief Medical Officer of Jazz Pharmaceuticals, Inc. Prior to joining Jazz in 2015, Dr. Smith served as Senior Vice President, Global Medical Affairs and Global Dermatology Head for Allergan plc. From 2008 to 2011, she held leadership positions in External Medical Relations and Global Development at AstraZeneca, and from 2002 to 2008 she held various senior management and clinical roles with Bristol-Myers Squibb, including Head of U.S. Clinical Operations. Dr. Smith currently is a member of the Board of Directors of Acceleron Pharma and a Board Advisor for the Australian Philanthropic 'Eliminate Cancer' Initiative. She received a B.App.Sc. in Biotechnology and a B.Sc. in Haematology from Curtin University of Technology, an M.D. from the University of Warwick, her Ph.D. in Oncology Molecular Genetics from the University of Western Australia, an M.B.A. from the University of New England in Australia, and a Master of Laws (L.L.M.) in Health Law from the University of Salford.
Joseph S. Zakrzewski has served as a member of Sangamo's Board of Directors since June 2017. Mr. Zakrzewski has over 25 years of experience in the biopharmaceutical industry with senior leadership experience in R&D, supply chain and manufacturing operations, business development and commercialization. From 2010 through 2013, he was Chairman and CEO of Amarin Pharmaceuticals, where he led the development and commercialization of the company's first product, Vascepa. Mr. Zakrzewski previously served as a Venture Partner with Orbimed Advisors, a venture capital firm, and as Chairman, President and CEO of Xcellerex, a privately held company focused on the commercialization of its proprietary manufacturing technology for biotherapeutics and vaccines. Earlier, he served as COO of Reliant Pharmaceuticals before its acquisition by GlaxoSmithKline in 2007 and held various executive positions at Eli Lilly & Company in the areas of R&D, manufacturing, finance and business development. Mr. Zakrzewski currently serves as a member of the board of directors of various public and private companies, including Acceleron Pharma, Amarin Pharmaceuticals Insulet Corporation and Onxeo SA where he serves as Chairman. Mr. Zakrzewski received a B.S. in Chemical Engineering and an M.S. in Biochemical Engineering from Drexel University, and an M.B.A. in Finance from Indiana University.